The creation of a national database will provide access to solid data on the diagnosis of myeloproliferative neoplasia for patients under 30, giving a true picture of their care. It will also make it possible to identify the biological samples (histological and molecular) available in routine laboratories, enabling teams of researchers and anatomopathologists to (re)perform certain analyses to re-evaluate diagnoses and search for hitherto unknown molecular prognostic factors.
Eligibility
Sex
ALL
Min age
0 Years
Max age
30 Years
Healthy volunteers
No
Inclusion Criteria:
* Patient diagnosed with non-LMC MPN before the age of 30 (PV or TE or MFP or PreMF) according to the 2016 WHO criteria.
* Signature of the consent form for participation in the FIMBANK project.
* Agreement to participate in the VYP study.
* Patient of legal age at the time of inclusion in VYP.
* Patient affiliated to a social security scheme
Exclusion Criteria:
* Refusal to participate by patients of full age
* Patient under legal protection (guardianship, curatorship, etc.)
Primary outcome measure(s)
Describe the epidemiological characteristics of the study population — at enrollment Description of MPN subtypes according to age
Describe the mutational landscape of these MPNs — at enrollment Rate of mutations JAK2/CALR/MPL
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.